nodes	percent_of_prediction	percent_of_DWPC	metapath
Ziprasidone—CYP3A4—bone cancer	0.464	1	CbGaD
Ziprasidone—HTR1B—dura mater—bone cancer	0.0147	0.144	CbGeAlD
Ziprasidone—HTR1D—dura mater—bone cancer	0.0142	0.14	CbGeAlD
Ziprasidone—DRD5—eyelid—bone cancer	0.014	0.138	CbGeAlD
Ziprasidone—HTR1B—trigeminal nerve—bone cancer	0.00631	0.0621	CbGeAlD
Ziprasidone—HTR1D—trigeminal nerve—bone cancer	0.00611	0.0601	CbGeAlD
Ziprasidone—HTR3A—cranial nerve—bone cancer	0.00536	0.0528	CbGeAlD
Ziprasidone—HRH1—nose—bone cancer	0.00463	0.0456	CbGeAlD
Ziprasidone—HTR1B—cranial nerve—bone cancer	0.00449	0.0443	CbGeAlD
Ziprasidone—HTR1D—cranial nerve—bone cancer	0.00435	0.0429	CbGeAlD
Ziprasidone—Lurasidone—CYP3A4—bone cancer	0.00373	0.623	CrCbGaD
Ziprasidone—HTR7—cranial nerve—bone cancer	0.00347	0.0341	CbGeAlD
Ziprasidone—HTR2A—trigeminal nerve—bone cancer	0.00303	0.0299	CbGeAlD
Ziprasidone—HTR2A—cranial nerve—bone cancer	0.00216	0.0213	CbGeAlD
Ziprasidone—HTR2A—vertebral column—bone cancer	0.00212	0.0209	CbGeAlD
Ziprasidone—HTR2A—hindlimb—bone cancer	0.00182	0.0179	CbGeAlD
Ziprasidone—HTR2A—appendage—bone cancer	0.00156	0.0154	CbGeAlD
Ziprasidone—H1F0—connective tissue—bone cancer	0.00116	0.0114	CbGeAlD
Ziprasidone—HTR1D—connective tissue—bone cancer	0.000898	0.00884	CbGeAlD
Ziprasidone—Aripiprazole—CYP3A4—bone cancer	0.000889	0.149	CrCbGaD
Ziprasidone—Trazodone—CYP3A4—bone cancer	0.000885	0.148	CrCbGaD
Ziprasidone—H1F0—tendon—bone cancer	0.000797	0.00785	CbGeAlD
Ziprasidone—H1F0—bone marrow—bone cancer	0.000772	0.0076	CbGeAlD
Ziprasidone—H1F0—spinal cord—bone cancer	0.000768	0.00757	CbGeAlD
Ziprasidone—HTR7—connective tissue—bone cancer	0.000715	0.00704	CbGeAlD
Ziprasidone—HTR1B—spinal cord—bone cancer	0.000615	0.00606	CbGeAlD
Ziprasidone—HTR2C—spinal cord—bone cancer	0.00059	0.00581	CbGeAlD
Ziprasidone—SLC6A4—spinal cord—bone cancer	0.000559	0.0055	CbGeAlD
Ziprasidone—HRH1—connective tissue—bone cancer	0.000534	0.00526	CbGeAlD
Ziprasidone—ADRA2A—connective tissue—bone cancer	0.000525	0.00517	CbGeAlD
Ziprasidone—HTR1A—spinal cord—bone cancer	0.000496	0.00489	CbGeAlD
Ziprasidone—HTR7—tendon—bone cancer	0.000492	0.00484	CbGeAlD
Ziprasidone—Clozapine—CYP3A4—bone cancer	0.000478	0.0799	CrCbGaD
Ziprasidone—HTR7—spinal cord—bone cancer	0.000474	0.00467	CbGeAlD
Ziprasidone—ADRA2C—tendon—bone cancer	0.000452	0.00445	CbGeAlD
Ziprasidone—HTR2A—connective tissue—bone cancer	0.000446	0.00439	CbGeAlD
Ziprasidone—KCNH2—bone marrow—bone cancer	0.000444	0.00437	CbGeAlD
Ziprasidone—KCNH2—spinal cord—bone cancer	0.000442	0.00435	CbGeAlD
Ziprasidone—ADRA2C—spinal cord—bone cancer	0.000436	0.00429	CbGeAlD
Ziprasidone—HRH1—tendon—bone cancer	0.000367	0.00362	CbGeAlD
Ziprasidone—ADRA2A—tendon—bone cancer	0.000361	0.00355	CbGeAlD
Ziprasidone—ADRA2A—spinal cord—bone cancer	0.000348	0.00342	CbGeAlD
Ziprasidone—HTR2A—tendon—bone cancer	0.000307	0.00302	CbGeAlD
Ziprasidone—HTR2A—spinal cord—bone cancer	0.000296	0.00291	CbGeAlD
Ziprasidone—Hyperglycaemia—Epirubicin—bone cancer	0.00029	0.00101	CcSEcCtD
Ziprasidone—Angina pectoris—Doxorubicin—bone cancer	0.000289	0.00101	CcSEcCtD
Ziprasidone—Epistaxis—Methotrexate—bone cancer	0.000289	0.001	CcSEcCtD
Ziprasidone—Pneumonia—Epirubicin—bone cancer	0.000288	0.001	CcSEcCtD
Ziprasidone—Infestation—Epirubicin—bone cancer	0.000286	0.000997	CcSEcCtD
Ziprasidone—Infestation NOS—Epirubicin—bone cancer	0.000286	0.000997	CcSEcCtD
Ziprasidone—Renal failure—Epirubicin—bone cancer	0.000281	0.00098	CcSEcCtD
Ziprasidone—Body temperature increased—Cisplatin—bone cancer	0.000281	0.000979	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Epirubicin—bone cancer	0.000281	0.000977	CcSEcCtD
Ziprasidone—Jaundice—Epirubicin—bone cancer	0.000279	0.000972	CcSEcCtD
Ziprasidone—Conjunctivitis—Epirubicin—bone cancer	0.000278	0.000969	CcSEcCtD
Ziprasidone—Dysuria—Doxorubicin—bone cancer	0.000278	0.000967	CcSEcCtD
Ziprasidone—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000276	0.000961	CcSEcCtD
Ziprasidone—Haemoglobin—Methotrexate—bone cancer	0.000276	0.000961	CcSEcCtD
Ziprasidone—Hepatitis—Methotrexate—bone cancer	0.000275	0.000956	CcSEcCtD
Ziprasidone—Haemorrhage—Methotrexate—bone cancer	0.000275	0.000956	CcSEcCtD
Ziprasidone—Sweating—Epirubicin—bone cancer	0.000274	0.000956	CcSEcCtD
Ziprasidone—Haematuria—Epirubicin—bone cancer	0.000273	0.00095	CcSEcCtD
Ziprasidone—Pharyngitis—Methotrexate—bone cancer	0.000273	0.000949	CcSEcCtD
Ziprasidone—Urinary tract disorder—Methotrexate—bone cancer	0.000271	0.000944	CcSEcCtD
Ziprasidone—Photosensitivity reaction—Doxorubicin—bone cancer	0.000271	0.000944	CcSEcCtD
Ziprasidone—Weight increased—Doxorubicin—bone cancer	0.00027	0.000941	CcSEcCtD
Ziprasidone—Epistaxis—Epirubicin—bone cancer	0.00027	0.00094	CcSEcCtD
Ziprasidone—Urethral disorder—Methotrexate—bone cancer	0.000269	0.000937	CcSEcCtD
Ziprasidone—Weight decreased—Doxorubicin—bone cancer	0.000269	0.000936	CcSEcCtD
Ziprasidone—Hyperglycaemia—Doxorubicin—bone cancer	0.000268	0.000933	CcSEcCtD
Ziprasidone—Pneumonia—Doxorubicin—bone cancer	0.000266	0.000928	CcSEcCtD
Ziprasidone—Infestation NOS—Doxorubicin—bone cancer	0.000265	0.000922	CcSEcCtD
Ziprasidone—Infestation—Doxorubicin—bone cancer	0.000265	0.000922	CcSEcCtD
Ziprasidone—Visual impairment—Methotrexate—bone cancer	0.000265	0.000922	CcSEcCtD
Ziprasidone—Hypersensitivity—Cisplatin—bone cancer	0.000262	0.000912	CcSEcCtD
Ziprasidone—Bradycardia—Epirubicin—bone cancer	0.000262	0.000911	CcSEcCtD
Ziprasidone—Renal failure—Doxorubicin—bone cancer	0.00026	0.000907	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Doxorubicin—bone cancer	0.00026	0.000904	CcSEcCtD
Ziprasidone—Haemoglobin—Epirubicin—bone cancer	0.000258	0.000899	CcSEcCtD
Ziprasidone—Jaundice—Doxorubicin—bone cancer	0.000258	0.000899	CcSEcCtD
Ziprasidone—Rhinitis—Epirubicin—bone cancer	0.000258	0.000897	CcSEcCtD
Ziprasidone—Conjunctivitis—Doxorubicin—bone cancer	0.000257	0.000897	CcSEcCtD
Ziprasidone—Haemorrhage—Epirubicin—bone cancer	0.000257	0.000895	CcSEcCtD
Ziprasidone—Hepatitis—Epirubicin—bone cancer	0.000257	0.000895	CcSEcCtD
Ziprasidone—Eye disorder—Methotrexate—bone cancer	0.000257	0.000894	CcSEcCtD
Ziprasidone—Tinnitus—Methotrexate—bone cancer	0.000256	0.000892	CcSEcCtD
Ziprasidone—Hypoaesthesia—Epirubicin—bone cancer	0.000256	0.00089	CcSEcCtD
Ziprasidone—Asthenia—Cisplatin—bone cancer	0.000255	0.000888	CcSEcCtD
Ziprasidone—Pharyngitis—Epirubicin—bone cancer	0.000255	0.000888	CcSEcCtD
Ziprasidone—Cardiac disorder—Methotrexate—bone cancer	0.000255	0.000887	CcSEcCtD
Ziprasidone—Sweating—Doxorubicin—bone cancer	0.000254	0.000884	CcSEcCtD
Ziprasidone—Urinary tract disorder—Epirubicin—bone cancer	0.000254	0.000884	CcSEcCtD
Ziprasidone—Oedema peripheral—Epirubicin—bone cancer	0.000253	0.000882	CcSEcCtD
Ziprasidone—Haematuria—Doxorubicin—bone cancer	0.000253	0.000879	CcSEcCtD
Ziprasidone—Connective tissue disorder—Epirubicin—bone cancer	0.000253	0.000879	CcSEcCtD
Ziprasidone—Urethral disorder—Epirubicin—bone cancer	0.000252	0.000877	CcSEcCtD
Ziprasidone—Epistaxis—Doxorubicin—bone cancer	0.00025	0.00087	CcSEcCtD
Ziprasidone—Angiopathy—Methotrexate—bone cancer	0.000249	0.000868	CcSEcCtD
Ziprasidone—Immune system disorder—Methotrexate—bone cancer	0.000248	0.000864	CcSEcCtD
Ziprasidone—Visual impairment—Epirubicin—bone cancer	0.000248	0.000862	CcSEcCtD
Ziprasidone—Mediastinal disorder—Methotrexate—bone cancer	0.000247	0.000862	CcSEcCtD
Ziprasidone—Chills—Methotrexate—bone cancer	0.000246	0.000858	CcSEcCtD
Ziprasidone—Diarrhoea—Cisplatin—bone cancer	0.000243	0.000847	CcSEcCtD
Ziprasidone—Alopecia—Methotrexate—bone cancer	0.000243	0.000845	CcSEcCtD
Ziprasidone—Bradycardia—Doxorubicin—bone cancer	0.000242	0.000843	CcSEcCtD
Ziprasidone—Mental disorder—Methotrexate—bone cancer	0.000241	0.000838	CcSEcCtD
Ziprasidone—Eye disorder—Epirubicin—bone cancer	0.00024	0.000836	CcSEcCtD
Ziprasidone—Tinnitus—Epirubicin—bone cancer	0.00024	0.000834	CcSEcCtD
Ziprasidone—Erythema—Methotrexate—bone cancer	0.000239	0.000832	CcSEcCtD
Ziprasidone—Malnutrition—Methotrexate—bone cancer	0.000239	0.000832	CcSEcCtD
Ziprasidone—Haemoglobin—Doxorubicin—bone cancer	0.000239	0.000832	CcSEcCtD
Ziprasidone—Cardiac disorder—Epirubicin—bone cancer	0.000238	0.000831	CcSEcCtD
Ziprasidone—Rhinitis—Doxorubicin—bone cancer	0.000238	0.00083	CcSEcCtD
Ziprasidone—Haemorrhage—Doxorubicin—bone cancer	0.000238	0.000828	CcSEcCtD
Ziprasidone—Hepatitis—Doxorubicin—bone cancer	0.000238	0.000828	CcSEcCtD
Ziprasidone—Hypoaesthesia—Doxorubicin—bone cancer	0.000237	0.000824	CcSEcCtD
Ziprasidone—Pharyngitis—Doxorubicin—bone cancer	0.000236	0.000822	CcSEcCtD
Ziprasidone—Urinary tract disorder—Doxorubicin—bone cancer	0.000235	0.000818	CcSEcCtD
Ziprasidone—Oedema peripheral—Doxorubicin—bone cancer	0.000234	0.000816	CcSEcCtD
Ziprasidone—Connective tissue disorder—Doxorubicin—bone cancer	0.000234	0.000814	CcSEcCtD
Ziprasidone—Angiopathy—Epirubicin—bone cancer	0.000233	0.000812	CcSEcCtD
Ziprasidone—Urethral disorder—Doxorubicin—bone cancer	0.000233	0.000812	CcSEcCtD
Ziprasidone—Immune system disorder—Epirubicin—bone cancer	0.000232	0.000808	CcSEcCtD
Ziprasidone—Mediastinal disorder—Epirubicin—bone cancer	0.000232	0.000807	CcSEcCtD
Ziprasidone—Back pain—Methotrexate—bone cancer	0.000231	0.000805	CcSEcCtD
Ziprasidone—Chills—Epirubicin—bone cancer	0.000231	0.000803	CcSEcCtD
Ziprasidone—Arrhythmia—Epirubicin—bone cancer	0.00023	0.000799	CcSEcCtD
Ziprasidone—Visual impairment—Doxorubicin—bone cancer	0.000229	0.000798	CcSEcCtD
Ziprasidone—Alopecia—Epirubicin—bone cancer	0.000227	0.000791	CcSEcCtD
Ziprasidone—Vomiting—Cisplatin—bone cancer	0.000226	0.000787	CcSEcCtD
Ziprasidone—Vision blurred—Methotrexate—bone cancer	0.000225	0.000785	CcSEcCtD
Ziprasidone—Mental disorder—Epirubicin—bone cancer	0.000225	0.000784	CcSEcCtD
Ziprasidone—Rash—Cisplatin—bone cancer	0.000224	0.000781	CcSEcCtD
Ziprasidone—Dermatitis—Cisplatin—bone cancer	0.000224	0.00078	CcSEcCtD
Ziprasidone—Malnutrition—Epirubicin—bone cancer	0.000224	0.000779	CcSEcCtD
Ziprasidone—Erythema—Epirubicin—bone cancer	0.000224	0.000779	CcSEcCtD
Ziprasidone—Eye disorder—Doxorubicin—bone cancer	0.000222	0.000774	CcSEcCtD
Ziprasidone—Tinnitus—Doxorubicin—bone cancer	0.000222	0.000772	CcSEcCtD
Ziprasidone—Anaemia—Methotrexate—bone cancer	0.000221	0.000769	CcSEcCtD
Ziprasidone—Cardiac disorder—Doxorubicin—bone cancer	0.000221	0.000768	CcSEcCtD
Ziprasidone—Flatulence—Epirubicin—bone cancer	0.00022	0.000768	CcSEcCtD
Ziprasidone—Back pain—Epirubicin—bone cancer	0.000216	0.000754	CcSEcCtD
Ziprasidone—Angiopathy—Doxorubicin—bone cancer	0.000216	0.000751	CcSEcCtD
Ziprasidone—Muscle spasms—Epirubicin—bone cancer	0.000215	0.000749	CcSEcCtD
Ziprasidone—Immune system disorder—Doxorubicin—bone cancer	0.000215	0.000748	CcSEcCtD
Ziprasidone—Vertigo—Methotrexate—bone cancer	0.000215	0.000748	CcSEcCtD
Ziprasidone—Mediastinal disorder—Doxorubicin—bone cancer	0.000214	0.000746	CcSEcCtD
Ziprasidone—Leukopenia—Methotrexate—bone cancer	0.000214	0.000745	CcSEcCtD
Ziprasidone—Chills—Doxorubicin—bone cancer	0.000213	0.000743	CcSEcCtD
Ziprasidone—Arrhythmia—Doxorubicin—bone cancer	0.000212	0.00074	CcSEcCtD
Ziprasidone—Nausea—Cisplatin—bone cancer	0.000211	0.000735	CcSEcCtD
Ziprasidone—Vision blurred—Epirubicin—bone cancer	0.000211	0.000734	CcSEcCtD
Ziprasidone—Alopecia—Doxorubicin—bone cancer	0.00021	0.000732	CcSEcCtD
Ziprasidone—Cough—Methotrexate—bone cancer	0.000209	0.000726	CcSEcCtD
Ziprasidone—Mental disorder—Doxorubicin—bone cancer	0.000208	0.000725	CcSEcCtD
Ziprasidone—Malnutrition—Doxorubicin—bone cancer	0.000207	0.000721	CcSEcCtD
Ziprasidone—Erythema—Doxorubicin—bone cancer	0.000207	0.000721	CcSEcCtD
Ziprasidone—Anaemia—Epirubicin—bone cancer	0.000207	0.00072	CcSEcCtD
Ziprasidone—Agitation—Epirubicin—bone cancer	0.000206	0.000716	CcSEcCtD
Ziprasidone—Flatulence—Doxorubicin—bone cancer	0.000204	0.00071	CcSEcCtD
Ziprasidone—Myalgia—Methotrexate—bone cancer	0.000204	0.000709	CcSEcCtD
Ziprasidone—Chest pain—Methotrexate—bone cancer	0.000204	0.000709	CcSEcCtD
Ziprasidone—Arthralgia—Methotrexate—bone cancer	0.000204	0.000709	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000202	0.000704	CcSEcCtD
Ziprasidone—Vertigo—Epirubicin—bone cancer	0.000201	0.0007	CcSEcCtD
Ziprasidone—Syncope—Epirubicin—bone cancer	0.000201	0.000699	CcSEcCtD
Ziprasidone—Leukopenia—Epirubicin—bone cancer	0.0002	0.000697	CcSEcCtD
Ziprasidone—Back pain—Doxorubicin—bone cancer	0.0002	0.000697	CcSEcCtD
Ziprasidone—Muscle spasms—Doxorubicin—bone cancer	0.000199	0.000693	CcSEcCtD
Ziprasidone—Palpitations—Epirubicin—bone cancer	0.000198	0.000688	CcSEcCtD
Ziprasidone—Confusional state—Methotrexate—bone cancer	0.000197	0.000685	CcSEcCtD
Ziprasidone—Loss of consciousness—Epirubicin—bone cancer	0.000197	0.000685	CcSEcCtD
Ziprasidone—Cough—Epirubicin—bone cancer	0.000195	0.00068	CcSEcCtD
Ziprasidone—Vision blurred—Doxorubicin—bone cancer	0.000195	0.000679	CcSEcCtD
Ziprasidone—Infection—Methotrexate—bone cancer	0.000194	0.000675	CcSEcCtD
Ziprasidone—Hypertension—Epirubicin—bone cancer	0.000193	0.000673	CcSEcCtD
Ziprasidone—Nervous system disorder—Methotrexate—bone cancer	0.000191	0.000666	CcSEcCtD
Ziprasidone—Anaemia—Doxorubicin—bone cancer	0.000191	0.000666	CcSEcCtD
Ziprasidone—Thrombocytopenia—Methotrexate—bone cancer	0.000191	0.000665	CcSEcCtD
Ziprasidone—Chest pain—Epirubicin—bone cancer	0.00019	0.000663	CcSEcCtD
Ziprasidone—Arthralgia—Epirubicin—bone cancer	0.00019	0.000663	CcSEcCtD
Ziprasidone—Myalgia—Epirubicin—bone cancer	0.00019	0.000663	CcSEcCtD
Ziprasidone—Agitation—Doxorubicin—bone cancer	0.00019	0.000662	CcSEcCtD
Ziprasidone—Anxiety—Epirubicin—bone cancer	0.00019	0.000661	CcSEcCtD
Ziprasidone—Skin disorder—Methotrexate—bone cancer	0.000189	0.00066	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000189	0.000659	CcSEcCtD
Ziprasidone—Hyperhidrosis—Methotrexate—bone cancer	0.000189	0.000657	CcSEcCtD
Ziprasidone—Dry mouth—Epirubicin—bone cancer	0.000186	0.000649	CcSEcCtD
Ziprasidone—Vertigo—Doxorubicin—bone cancer	0.000186	0.000648	CcSEcCtD
Ziprasidone—Anorexia—Methotrexate—bone cancer	0.000186	0.000648	CcSEcCtD
Ziprasidone—Syncope—Doxorubicin—bone cancer	0.000186	0.000646	CcSEcCtD
Ziprasidone—Leukopenia—Doxorubicin—bone cancer	0.000185	0.000645	CcSEcCtD
Ziprasidone—Confusional state—Epirubicin—bone cancer	0.000184	0.000641	CcSEcCtD
Ziprasidone—Palpitations—Doxorubicin—bone cancer	0.000183	0.000637	CcSEcCtD
Ziprasidone—Hypotension—Methotrexate—bone cancer	0.000182	0.000635	CcSEcCtD
Ziprasidone—Loss of consciousness—Doxorubicin—bone cancer	0.000182	0.000634	CcSEcCtD
Ziprasidone—Infection—Epirubicin—bone cancer	0.000181	0.000632	CcSEcCtD
Ziprasidone—Cough—Doxorubicin—bone cancer	0.000181	0.000629	CcSEcCtD
Ziprasidone—Shock—Epirubicin—bone cancer	0.00018	0.000626	CcSEcCtD
Ziprasidone—Nervous system disorder—Epirubicin—bone cancer	0.000179	0.000623	CcSEcCtD
Ziprasidone—Thrombocytopenia—Epirubicin—bone cancer	0.000179	0.000622	CcSEcCtD
Ziprasidone—Hypertension—Doxorubicin—bone cancer	0.000179	0.000622	CcSEcCtD
Ziprasidone—Tachycardia—Epirubicin—bone cancer	0.000178	0.000621	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000178	0.000619	CcSEcCtD
Ziprasidone—Skin disorder—Epirubicin—bone cancer	0.000177	0.000618	CcSEcCtD
Ziprasidone—Hyperhidrosis—Epirubicin—bone cancer	0.000176	0.000615	CcSEcCtD
Ziprasidone—Insomnia—Methotrexate—bone cancer	0.000176	0.000614	CcSEcCtD
Ziprasidone—Arthralgia—Doxorubicin—bone cancer	0.000176	0.000614	CcSEcCtD
Ziprasidone—Chest pain—Doxorubicin—bone cancer	0.000176	0.000614	CcSEcCtD
Ziprasidone—Myalgia—Doxorubicin—bone cancer	0.000176	0.000614	CcSEcCtD
Ziprasidone—Anxiety—Doxorubicin—bone cancer	0.000176	0.000612	CcSEcCtD
Ziprasidone—Paraesthesia—Methotrexate—bone cancer	0.000175	0.00061	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000175	0.000609	CcSEcCtD
Ziprasidone—Anorexia—Epirubicin—bone cancer	0.000174	0.000606	CcSEcCtD
Ziprasidone—Dyspnoea—Methotrexate—bone cancer	0.000174	0.000606	CcSEcCtD
Ziprasidone—Somnolence—Methotrexate—bone cancer	0.000173	0.000604	CcSEcCtD
Ziprasidone—Dry mouth—Doxorubicin—bone cancer	0.000172	0.0006	CcSEcCtD
Ziprasidone—Dyspepsia—Methotrexate—bone cancer	0.000172	0.000598	CcSEcCtD
Ziprasidone—Hypotension—Epirubicin—bone cancer	0.000171	0.000594	CcSEcCtD
Ziprasidone—Confusional state—Doxorubicin—bone cancer	0.00017	0.000593	CcSEcCtD
Ziprasidone—Decreased appetite—Methotrexate—bone cancer	0.00017	0.000591	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Methotrexate—bone cancer	0.000168	0.000587	CcSEcCtD
Ziprasidone—Fatigue—Methotrexate—bone cancer	0.000168	0.000586	CcSEcCtD
Ziprasidone—Infection—Doxorubicin—bone cancer	0.000168	0.000584	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000166	0.000579	CcSEcCtD
Ziprasidone—Shock—Doxorubicin—bone cancer	0.000166	0.000579	CcSEcCtD
Ziprasidone—Nervous system disorder—Doxorubicin—bone cancer	0.000166	0.000577	CcSEcCtD
Ziprasidone—Thrombocytopenia—Doxorubicin—bone cancer	0.000165	0.000576	CcSEcCtD
Ziprasidone—Insomnia—Epirubicin—bone cancer	0.000165	0.000575	CcSEcCtD
Ziprasidone—Tachycardia—Doxorubicin—bone cancer	0.000165	0.000574	CcSEcCtD
Ziprasidone—Skin disorder—Doxorubicin—bone cancer	0.000164	0.000571	CcSEcCtD
Ziprasidone—Paraesthesia—Epirubicin—bone cancer	0.000164	0.000571	CcSEcCtD
Ziprasidone—Hyperhidrosis—Doxorubicin—bone cancer	0.000163	0.000569	CcSEcCtD
Ziprasidone—Dyspnoea—Epirubicin—bone cancer	0.000163	0.000567	CcSEcCtD
Ziprasidone—Somnolence—Epirubicin—bone cancer	0.000162	0.000565	CcSEcCtD
Ziprasidone—Anorexia—Doxorubicin—bone cancer	0.000161	0.000561	CcSEcCtD
Ziprasidone—Feeling abnormal—Methotrexate—bone cancer	0.000161	0.00056	CcSEcCtD
Ziprasidone—Dyspepsia—Epirubicin—bone cancer	0.000161	0.00056	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Methotrexate—bone cancer	0.00016	0.000556	CcSEcCtD
Ziprasidone—Decreased appetite—Epirubicin—bone cancer	0.000159	0.000553	CcSEcCtD
Ziprasidone—Hypotension—Doxorubicin—bone cancer	0.000158	0.00055	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Epirubicin—bone cancer	0.000158	0.000549	CcSEcCtD
Ziprasidone—Fatigue—Epirubicin—bone cancer	0.000157	0.000548	CcSEcCtD
Ziprasidone—Constipation—Epirubicin—bone cancer	0.000156	0.000544	CcSEcCtD
Ziprasidone—Urticaria—Methotrexate—bone cancer	0.000155	0.00054	CcSEcCtD
Ziprasidone—Abdominal pain—Methotrexate—bone cancer	0.000154	0.000537	CcSEcCtD
Ziprasidone—Body temperature increased—Methotrexate—bone cancer	0.000154	0.000537	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000154	0.000536	CcSEcCtD
Ziprasidone—Insomnia—Doxorubicin—bone cancer	0.000153	0.000532	CcSEcCtD
Ziprasidone—Paraesthesia—Doxorubicin—bone cancer	0.000152	0.000528	CcSEcCtD
Ziprasidone—Dyspnoea—Doxorubicin—bone cancer	0.000151	0.000524	CcSEcCtD
Ziprasidone—Feeling abnormal—Epirubicin—bone cancer	0.00015	0.000524	CcSEcCtD
Ziprasidone—Somnolence—Doxorubicin—bone cancer	0.00015	0.000523	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Epirubicin—bone cancer	0.000149	0.00052	CcSEcCtD
Ziprasidone—Dyspepsia—Doxorubicin—bone cancer	0.000149	0.000518	CcSEcCtD
Ziprasidone—Decreased appetite—Doxorubicin—bone cancer	0.000147	0.000511	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000146	0.000508	CcSEcCtD
Ziprasidone—Fatigue—Doxorubicin—bone cancer	0.000146	0.000507	CcSEcCtD
Ziprasidone—Urticaria—Epirubicin—bone cancer	0.000145	0.000505	CcSEcCtD
Ziprasidone—Constipation—Doxorubicin—bone cancer	0.000144	0.000503	CcSEcCtD
Ziprasidone—Abdominal pain—Epirubicin—bone cancer	0.000144	0.000503	CcSEcCtD
Ziprasidone—Body temperature increased—Epirubicin—bone cancer	0.000144	0.000503	CcSEcCtD
Ziprasidone—Hypersensitivity—Methotrexate—bone cancer	0.000144	0.000501	CcSEcCtD
Ziprasidone—Asthenia—Methotrexate—bone cancer	0.00014	0.000487	CcSEcCtD
Ziprasidone—Feeling abnormal—Doxorubicin—bone cancer	0.000139	0.000485	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Doxorubicin—bone cancer	0.000138	0.000481	CcSEcCtD
Ziprasidone—Hypersensitivity—Epirubicin—bone cancer	0.000135	0.000468	CcSEcCtD
Ziprasidone—Urticaria—Doxorubicin—bone cancer	0.000134	0.000467	CcSEcCtD
Ziprasidone—Abdominal pain—Doxorubicin—bone cancer	0.000134	0.000465	CcSEcCtD
Ziprasidone—Body temperature increased—Doxorubicin—bone cancer	0.000134	0.000465	CcSEcCtD
Ziprasidone—Diarrhoea—Methotrexate—bone cancer	0.000133	0.000465	CcSEcCtD
Ziprasidone—Asthenia—Epirubicin—bone cancer	0.000131	0.000456	CcSEcCtD
Ziprasidone—Dizziness—Methotrexate—bone cancer	0.000129	0.000449	CcSEcCtD
Ziprasidone—Diarrhoea—Epirubicin—bone cancer	0.000125	0.000435	CcSEcCtD
Ziprasidone—Hypersensitivity—Doxorubicin—bone cancer	0.000124	0.000433	CcSEcCtD
Ziprasidone—Vomiting—Methotrexate—bone cancer	0.000124	0.000432	CcSEcCtD
Ziprasidone—Rash—Methotrexate—bone cancer	0.000123	0.000428	CcSEcCtD
Ziprasidone—Dermatitis—Methotrexate—bone cancer	0.000123	0.000428	CcSEcCtD
Ziprasidone—Headache—Methotrexate—bone cancer	0.000122	0.000426	CcSEcCtD
Ziprasidone—Asthenia—Doxorubicin—bone cancer	0.000121	0.000422	CcSEcCtD
Ziprasidone—Dizziness—Epirubicin—bone cancer	0.000121	0.00042	CcSEcCtD
Ziprasidone—Vomiting—Epirubicin—bone cancer	0.000116	0.000404	CcSEcCtD
Ziprasidone—Nausea—Methotrexate—bone cancer	0.000116	0.000404	CcSEcCtD
Ziprasidone—Diarrhoea—Doxorubicin—bone cancer	0.000116	0.000403	CcSEcCtD
Ziprasidone—Rash—Epirubicin—bone cancer	0.000115	0.000401	CcSEcCtD
Ziprasidone—Dermatitis—Epirubicin—bone cancer	0.000115	0.0004	CcSEcCtD
Ziprasidone—Headache—Epirubicin—bone cancer	0.000114	0.000398	CcSEcCtD
Ziprasidone—Dizziness—Doxorubicin—bone cancer	0.000112	0.000389	CcSEcCtD
Ziprasidone—Nausea—Epirubicin—bone cancer	0.000108	0.000378	CcSEcCtD
Ziprasidone—Vomiting—Doxorubicin—bone cancer	0.000107	0.000374	CcSEcCtD
Ziprasidone—Rash—Doxorubicin—bone cancer	0.000107	0.000371	CcSEcCtD
Ziprasidone—Dermatitis—Doxorubicin—bone cancer	0.000106	0.000371	CcSEcCtD
Ziprasidone—Headache—Doxorubicin—bone cancer	0.000106	0.000369	CcSEcCtD
Ziprasidone—Nausea—Doxorubicin—bone cancer	0.0001	0.000349	CcSEcCtD
Ziprasidone—CHRM2—Signaling Pathways—ATF1—bone cancer	2.13e-05	0.000152	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—ATF1—bone cancer	2.13e-05	0.000151	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—GNA11—bone cancer	2.13e-05	0.000151	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—IL3—bone cancer	2.12e-05	0.00015	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—IL3—bone cancer	2.11e-05	0.00015	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—CYP3A4—bone cancer	2.11e-05	0.00015	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—IL3—bone cancer	2.11e-05	0.00015	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—IL3—bone cancer	2.1e-05	0.000149	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TGFBR2—bone cancer	2.1e-05	0.000149	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TGFBR2—bone cancer	2.09e-05	0.000148	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—IL3—bone cancer	2.08e-05	0.000148	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—IL3—bone cancer	2.07e-05	0.000147	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—IGF1R—bone cancer	2.04e-05	0.000145	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TGFBR2—bone cancer	2.03e-05	0.000144	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TGFBR2—bone cancer	2e-05	0.000142	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—ATF1—bone cancer	1.98e-05	0.00014	CbGpPWpGaD
Ziprasidone—ADRA2B—Hemostasis—TP53—bone cancer	1.98e-05	0.00014	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—IGF1R—bone cancer	1.97e-05	0.00014	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—MDM2—bone cancer	1.97e-05	0.00014	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—GSTP1—bone cancer	1.97e-05	0.00014	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—IGF1R—bone cancer	1.96e-05	0.000139	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—JUN—bone cancer	1.94e-05	0.000138	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—KIT—bone cancer	1.93e-05	0.000137	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—KIT—bone cancer	1.93e-05	0.000137	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IL3—bone cancer	1.93e-05	0.000137	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—KIT—bone cancer	1.92e-05	0.000136	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—ENO2—bone cancer	1.91e-05	0.000136	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—IGF1R—bone cancer	1.91e-05	0.000136	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—MMP9—bone cancer	1.89e-05	0.000134	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—IGF1R—bone cancer	1.88e-05	0.000133	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—KIT—bone cancer	1.88e-05	0.000133	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—KIT—bone cancer	1.85e-05	0.000131	CbGpPWpGaD
Ziprasidone—ADRA2C—Hemostasis—TP53—bone cancer	1.85e-05	0.000131	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TGFBR2—bone cancer	1.84e-05	0.000131	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—KIT—bone cancer	1.82e-05	0.00013	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—BRAF—bone cancer	1.82e-05	0.000129	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—BRAF—bone cancer	1.82e-05	0.000129	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TGFBR2—bone cancer	1.81e-05	0.000129	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TGFBR2—bone cancer	1.81e-05	0.000128	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—GSTP1—bone cancer	1.81e-05	0.000128	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—BRAF—bone cancer	1.8e-05	0.000128	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TGFBR2—bone cancer	1.8e-05	0.000128	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TGFBR2—bone cancer	1.8e-05	0.000128	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TGFBR2—bone cancer	1.78e-05	0.000126	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TGFBR2—bone cancer	1.77e-05	0.000126	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—DHFR—bone cancer	1.77e-05	0.000126	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—BRAF—bone cancer	1.77e-05	0.000125	CbGpPWpGaD
Ziprasidone—HTR6—Signaling by GPCR—EGFR—bone cancer	1.76e-05	0.000125	CbGpPWpGaD
Ziprasidone—HTR7—Signaling by GPCR—EGFR—bone cancer	1.76e-05	0.000125	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling by GPCR—EGFR—bone cancer	1.75e-05	0.000124	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—KIT—bone cancer	1.75e-05	0.000124	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—BRAF—bone cancer	1.74e-05	0.000123	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—IGF1R—bone cancer	1.73e-05	0.000123	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—JUN—bone cancer	1.72e-05	0.000122	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—BRAF—bone cancer	1.71e-05	0.000122	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling by GPCR—EGFR—bone cancer	1.71e-05	0.000122	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—IGF1R—bone cancer	1.71e-05	0.000121	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—IGF1R—bone cancer	1.7e-05	0.000121	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—IGF1R—bone cancer	1.7e-05	0.00012	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—IGF1R—bone cancer	1.69e-05	0.00012	CbGpPWpGaD
Ziprasidone—DRD4—Signaling by GPCR—EGFR—bone cancer	1.68e-05	0.00012	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—IGF1R—bone cancer	1.67e-05	0.000119	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—IGF1R—bone cancer	1.67e-05	0.000119	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—MMP9—bone cancer	1.67e-05	0.000118	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—KIT—bone cancer	1.66e-05	0.000118	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling by GPCR—EGFR—bone cancer	1.66e-05	0.000118	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—GNA11—bone cancer	1.66e-05	0.000118	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TGFBR2—bone cancer	1.65e-05	0.000117	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—KIT—bone cancer	1.64e-05	0.000117	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—BRAF—bone cancer	1.64e-05	0.000117	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—ENO2—bone cancer	1.62e-05	0.000115	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling by GPCR—EGFR—bone cancer	1.59e-05	0.000113	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—BRAF—bone cancer	1.56e-05	0.000111	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IGF1R—bone cancer	1.55e-05	0.00011	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—BRAF—bone cancer	1.54e-05	0.00011	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—EGFR—bone cancer	1.52e-05	0.000108	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—MDM2—bone cancer	1.52e-05	0.000108	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—MDM2—bone cancer	1.52e-05	0.000108	CbGpPWpGaD
Ziprasidone—DRD1—Signaling by GPCR—EGFR—bone cancer	1.52e-05	0.000108	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—MDM2—bone cancer	1.51e-05	0.000107	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—CYP3A4—bone cancer	1.5e-05	0.000107	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—DHFR—bone cancer	1.5e-05	0.000107	CbGpPWpGaD
Ziprasidone—ADRA2A—Hemostasis—TP53—bone cancer	1.5e-05	0.000106	CbGpPWpGaD
Ziprasidone—DRD3—Signaling by GPCR—EGFR—bone cancer	1.5e-05	0.000106	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—KIT—bone cancer	1.48e-05	0.000105	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—MDM2—bone cancer	1.48e-05	0.000105	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—MDM2—bone cancer	1.46e-05	0.000103	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—MDM2—bone cancer	1.44e-05	0.000102	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—KIT—bone cancer	1.43e-05	0.000102	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—KIT—bone cancer	1.42e-05	0.000101	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—GNA11—bone cancer	1.4e-05	9.97e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—BRAF—bone cancer	1.39e-05	9.9e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—KIT—bone cancer	1.39e-05	9.84e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—MDM2—bone cancer	1.38e-05	9.77e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—KIT—bone cancer	1.36e-05	9.68e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling by GPCR—EGFR—bone cancer	1.35e-05	9.59e-05	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—EGFR—bone cancer	1.35e-05	9.58e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—BRAF—bone cancer	1.35e-05	9.55e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—BRAF—bone cancer	1.34e-05	9.51e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—JUN—bone cancer	1.32e-05	9.4e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—JUN—bone cancer	1.32e-05	9.39e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—JUN—bone cancer	1.31e-05	9.33e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—MDM2—bone cancer	1.31e-05	9.31e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—EGFR—bone cancer	1.3e-05	9.26e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—BRAF—bone cancer	1.3e-05	9.25e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—EGFR—bone cancer	1.3e-05	9.21e-05	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—PTGS2—bone cancer	1.3e-05	9.2e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—MDM2—bone cancer	1.29e-05	9.19e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—MMP9—bone cancer	1.29e-05	9.15e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—MMP9—bone cancer	1.29e-05	9.14e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—JUN—bone cancer	1.29e-05	9.13e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—GSTP1—bone cancer	1.28e-05	9.12e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—BRAF—bone cancer	1.28e-05	9.1e-05	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—TP53—bone cancer	1.28e-05	9.08e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—MMP9—bone cancer	1.28e-05	9.08e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—CYP3A4—bone cancer	1.27e-05	9.04e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.27e-05	8.99e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—JUN—bone cancer	1.27e-05	8.99e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—EGFR—bone cancer	1.26e-05	8.96e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—PTGS2—bone cancer	1.26e-05	8.93e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—KIT—bone cancer	1.26e-05	8.92e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—MMP9—bone cancer	1.25e-05	8.89e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—ENO2—bone cancer	1.25e-05	8.87e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—JUN—bone cancer	1.25e-05	8.87e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—EGFR—bone cancer	1.24e-05	8.82e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—KIT—bone cancer	1.24e-05	8.78e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—KIT—bone cancer	1.23e-05	8.76e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—MMP9—bone cancer	1.23e-05	8.75e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—KIT—bone cancer	1.23e-05	8.73e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—KIT—bone cancer	1.23e-05	8.71e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—MMP9—bone cancer	1.21e-05	8.63e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—KIT—bone cancer	1.21e-05	8.62e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—KIT—bone cancer	1.21e-05	8.6e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—JUN—bone cancer	1.2e-05	8.49e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—BRAF—bone cancer	1.18e-05	8.39e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—MDM2—bone cancer	1.17e-05	8.29e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—MMP9—bone cancer	1.16e-05	8.26e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—BRAF—bone cancer	1.16e-05	8.25e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—BRAF—bone cancer	1.16e-05	8.24e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—DHFR—bone cancer	1.16e-05	8.23e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—BRAF—bone cancer	1.16e-05	8.21e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—BRAF—bone cancer	1.15e-05	8.18e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—EGFR—bone cancer	1.15e-05	8.13e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—BRAF—bone cancer	1.14e-05	8.1e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—JUN—bone cancer	1.14e-05	8.09e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—BRAF—bone cancer	1.14e-05	8.08e-05	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—TP53—bone cancer	1.13e-05	8.04e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—MDM2—bone cancer	1.13e-05	8.01e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—EGFR—bone cancer	1.13e-05	8e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—KIT—bone cancer	1.13e-05	7.99e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—JUN—bone cancer	1.12e-05	7.98e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—EGFR—bone cancer	1.12e-05	7.98e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—MDM2—bone cancer	1.12e-05	7.96e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—EGFR—bone cancer	1.12e-05	7.96e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—EGFR—bone cancer	1.12e-05	7.93e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—PTGS2—bone cancer	1.11e-05	7.91e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—MMP9—bone cancer	1.11e-05	7.87e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—EGFR—bone cancer	1.11e-05	7.86e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—EGFR—bone cancer	1.1e-05	7.83e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—MMP9—bone cancer	1.09e-05	7.77e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MDM2—bone cancer	1.09e-05	7.75e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—GSTP1—bone cancer	1.09e-05	7.73e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—GNA11—bone cancer	1.08e-05	7.69e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MDM2—bone cancer	1.07e-05	7.62e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—BRAF—bone cancer	1.06e-05	7.51e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—EGFR—bone cancer	1.04e-05	7.39e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—EGFR—bone cancer	1.04e-05	7.38e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—EGFR—bone cancer	1.03e-05	7.33e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—EGFR—bone cancer	1.02e-05	7.28e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—PTGS2—bone cancer	1.02e-05	7.25e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—JUN—bone cancer	1.02e-05	7.21e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—EGFR—bone cancer	1.01e-05	7.18e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—EGFR—bone cancer	9.95e-06	7.07e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MDM2—bone cancer	9.9e-06	7.03e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—MMP9—bone cancer	9.88e-06	7.01e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—EGFR—bone cancer	9.82e-06	6.97e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—JUN—bone cancer	9.8e-06	6.96e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—JUN—bone cancer	9.75e-06	6.92e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MDM2—bone cancer	9.74e-06	6.92e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MDM2—bone cancer	9.72e-06	6.9e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MDM2—bone cancer	9.69e-06	6.88e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MDM2—bone cancer	9.66e-06	6.86e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MDM2—bone cancer	9.56e-06	6.79e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MDM2—bone cancer	9.54e-06	6.77e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—MMP9—bone cancer	9.53e-06	6.77e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—MMP9—bone cancer	9.48e-06	6.74e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—JUN—bone cancer	9.48e-06	6.73e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—EGFR—bone cancer	9.4e-06	6.68e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—PTGS2—bone cancer	9.36e-06	6.65e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—JUN—bone cancer	9.33e-06	6.63e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MMP9—bone cancer	9.22e-06	6.55e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MMP9—bone cancer	9.08e-06	6.45e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—EGFR—bone cancer	8.96e-06	6.36e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MDM2—bone cancer	8.86e-06	6.29e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—EGFR—bone cancer	8.84e-06	6.28e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—TP53—bone cancer	8.74e-06	6.21e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—TP53—bone cancer	8.73e-06	6.2e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—TP53—bone cancer	8.67e-06	6.16e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—JUN—bone cancer	8.6e-06	6.11e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—TP53—bone cancer	8.49e-06	6.03e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—JUN—bone cancer	8.47e-06	6.01e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—JUN—bone cancer	8.45e-06	6e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—JUN—bone cancer	8.42e-06	5.98e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—GSTP1—bone cancer	8.4e-06	5.97e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—JUN—bone cancer	8.39e-06	5.96e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MMP9—bone cancer	8.37e-06	5.94e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—TP53—bone cancer	8.36e-06	5.93e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—JUN—bone cancer	8.31e-06	5.9e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—JUN—bone cancer	8.29e-06	5.89e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—TP53—bone cancer	8.24e-06	5.85e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MMP9—bone cancer	8.24e-06	5.85e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MMP9—bone cancer	8.22e-06	5.84e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MMP9—bone cancer	8.19e-06	5.82e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MMP9—bone cancer	8.17e-06	5.8e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MMP9—bone cancer	8.09e-06	5.74e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MMP9—bone cancer	8.06e-06	5.73e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—EGFR—bone cancer	7.98e-06	5.67e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—TP53—bone cancer	7.89e-06	5.61e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—EGFR—bone cancer	7.7e-06	5.47e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—JUN—bone cancer	7.7e-06	5.47e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—EGFR—bone cancer	7.66e-06	5.44e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—TP53—bone cancer	7.52e-06	5.34e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MMP9—bone cancer	7.49e-06	5.32e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—EGFR—bone cancer	7.45e-06	5.29e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—TP53—bone cancer	7.42e-06	5.27e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—EGFR—bone cancer	7.34e-06	5.21e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—EGFR—bone cancer	6.76e-06	4.8e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—TP53—bone cancer	6.7e-06	4.76e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PTGS2—bone cancer	6.66e-06	4.73e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—EGFR—bone cancer	6.66e-06	4.73e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—EGFR—bone cancer	6.64e-06	4.72e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—EGFR—bone cancer	6.62e-06	4.7e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—EGFR—bone cancer	6.6e-06	4.69e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—EGFR—bone cancer	6.53e-06	4.64e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—EGFR—bone cancer	6.52e-06	4.63e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TP53—bone cancer	6.47e-06	4.59e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TP53—bone cancer	6.44e-06	4.57e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TP53—bone cancer	6.26e-06	4.44e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TP53—bone cancer	6.16e-06	4.37e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—EGFR—bone cancer	6.05e-06	4.3e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TP53—bone cancer	5.68e-06	4.03e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PTGS2—bone cancer	5.64e-06	4e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TP53—bone cancer	5.59e-06	3.97e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TP53—bone cancer	5.58e-06	3.96e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TP53—bone cancer	5.56e-06	3.95e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TP53—bone cancer	5.54e-06	3.93e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TP53—bone cancer	5.49e-06	3.9e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TP53—bone cancer	5.47e-06	3.89e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TP53—bone cancer	5.08e-06	3.61e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PTGS2—bone cancer	4.35e-06	3.09e-05	CbGpPWpGaD
